Skip to main content
    T

    Trinity Biotech plc (TRIB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.67
    -0.43 (-7.05%)

    Market Cap: $4.96M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Trinity Biotech plc (TRIB) Financials: Revenue, Profit and Cash Flow

    Updated Apr 30, 2026. Financial statements from company filings, amounts in US dollars.

    Trinity Biotech reported revenue of $43.78M for the fiscal year ended Dec 31, 2025, down 28.9% from the year before. That year, net income was -$37.38M with a net margin of -85.4%, operating cash flow was -$5.93M and free cash flow was -$12.15M. The quarter ended Mar 31, 2026 had revenue of $11.06M and net income of -$17.46M.

    Revenue and Margins

    The operating margin was -26.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $99.61M, a compound annual decline of 8.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$43.78M-28.9%38.6%-26.1%-85.4%
    Dec 2024$61.55M+8.3%34.8%-34.4%-51.6%
    Dec 2023$56.83M-9.1%34.2%-47.6%-42.3%
    Dec 2022$62.52M-23.0%35.3%-24.4%-65.6%
    Dec 2021$81.15M-20.4%41.2%4.9%1.1%
    Dec 2020$101.98M+12.8%47.6%0.1%-6.3%
    Dec 2019$90.44M-6.8%42.2%1.0%-4.5%
    Dec 2018$97.03M-2.1%42.7%3.4%2.5%
    Dec 2017$99.14M-0.5%42.3%5.5%-40.6%
    Dec 2016$99.61MN/A43.3%7.5%-101.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$43.78M$61.55M$56.83M$62.52M$81.15M$101.98M$90.44M$97.03M$99.14M$99.61M
    Cost of revenue$26.90M$40.11M$37.38M$52.73M$54.89M$53.40M$52.31M$55.59M$57.25M$56.52M
    Gross profit$16.89M$21.44M$19.45M$22.05M$33.45M$48.58M$38.12M$41.45M$41.89M$43.09M
    Research and development$3.63M$4.54M$4.38M$4.14M$4.50M$5.08M$5.33M$5.37M$5.66M$5.04M
    Operating income-$11.42M-$21.16M-$27.05M-$15.27M$3.94M$82.00K$872.00K$3.30M$5.48M$7.49M
    Net income-$37.38M-$31.79M-$24.02M-$41.00M$875.00K-$6.39M-$4.07M$2.39M-$40.27M-$100.63M
    EBITDAN/A-$16.91M-$24.10MN/A$10.59M$3.19MN/AN/AN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$11.06M$11.06M$14.25M$10.98M$7.58M$15.86M$15.15M$15.84M$14.70M$14.70M$14.68M$13.90M
    Gross profit$3.55M$3.55M$6.09M$4.33M$1.57M$4.88M$5.31M$5.73M$5.00M$5.00M$4.28M$5.03M
    Operating income-$2.94M-$2.94M-$536.57K-$3.04M-$4.73M-$11.51M-$2.56M-$1.67M-$3.04M-$3.07M-$4.50M-$14.85M
    Net income-$17.46M-$17.46M-$5.11M-$6.05M-$8.80M-$16.96M-$4.76M-$6.76M-$3.32M-$3.32M-$6.72M-$5.99M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $127.14M exceeded cash and equivalents by $122.00M. Shareholder equity was negative, at -$71.98M, as total liabilities of $177.15M exceeded total assets of $105.17M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$105.17M$103.29M$59.44M$92.10M$118.89M$130.40M$131.07M$151.24M$192.62M$249.59M
    Current assets$35.90M$41.12M$39.04M$46.67M$72.69M$83.30M$71.39M$86.66M$112.59M$133.49M
    Cash and equivalents$5.14M$5.17M$3.69M$6.58M$25.91M$27.33M$16.40M$30.28M$57.61M$77.11M
    Total liabilities$177.15M$138.47M$83.38M$94.28M$119.21M$132.62M$126.36M$107.18M$127.42M$140.87M
    Short-term debt$110.81M$2.50M$1.90M$1.89M$85.29M$5.06M$2.40M$436.00K$354.00K$273.00K
    Long-term debt$16.33M$87.79M$54.65M$58.05MN/A$83.88M$82.02M$81.38M$92.95M$92.23M
    Shareholder equity-$71.98M-$35.18M-$23.95M-$2.18M-$319.00K-$2.22M$4.71M$44.05M$65.20M$108.73M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$105.17M$105.17M$103.71M$99.63M$99.79M$103.29M$97.45M$94.36M$90.31M$90.31M$63.60M$71.99M
    Total liabilities$177.15M$177.15M$158.43M$149.17M$143.41M$138.47M$123.79M$123.75M$113.16M$113.16M$81.08M$83.37M
    Cash and equivalents$5.14M$5.14M$1.34M$1.55M$4.07M$5.17M$2.84M$5.32M$5.78M$5.78M-$12.52M-$13.19M
    Shareholder equity-$71.98M-$71.98M-$54.72M-$49.54M-$43.63M-$35.18M-$26.34M-$29.40M-$22.86M-$22.86M-$17.49M-$11.38M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$5.93M-$4.19M-$11.56M-$921.00K$13.24M$23.75M$5.47M$6.93M$12.11M$13.77M
    Capital expenditures$6.22M$10.06M$803.00K$5.98M$8.69M$10.20M$15.36M$17.29M$16.37M$22.28M
    Free cash flow-$12.15M-$14.26M-$12.36M-$6.90M$4.55M$13.56M-$9.88M-$10.35M-$4.25M-$8.51M
    Dividends paid$0$0$0$0$0$0$0$0$0$5.17M
    Investing cash flow-$6.22M-$22.97M$24.76M-$5.98M-$8.69M-$10.20M-$15.36M-$17.29M-$16.37M-$22.28M
    Financing cash flow$12.05M$28.81M-$16.04M-$12.32M-$6.02M-$2.72M-$4.00M-$16.98M-$15.25M-$16.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$1.55M-$1.55M-$71.45K-$1.67M-$2.96M$3.35M-$3.62M-$1.10M-$2.82M-$4.82M-$4.66M-$4.42M
    Capital expenditures$11.14K$11.14K$5.66K$37.70K$56.04K$2.74M$2.70M$3.17M$1.46M$1.46M$620.00K$564.00K
    Free cash flow-$1.56M-$1.56M-$77.11K-$1.71M-$3.02M$615.00K-$6.32M-$4.27M-$4.28M-$6.29M-$5.28M-$4.98M
    Last 12 quarters

    Frequently Asked Questions About TRIB

    What is Trinity Biotech's annual revenue?

    Trinity Biotech reported revenue of $43.78M for the fiscal year ended Dec 31, 2025.

    How fast is Trinity Biotech's revenue growing?

    Revenue was down 28.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -11.2%.

    Is Trinity Biotech profitable?

    No. Trinity Biotech reported net income of -$37.38M for the fiscal year ended Dec 31, 2025, with a net margin of -85.4%.

    How much free cash flow does TRIB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.93M minus capital expenditures of $6.22M produced free cash flow of -$12.15M.

    How much debt does Trinity Biotech have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $16.33M, short-term debt of $110.81M and cash and equivalents of $5.14M.